XLXinyu Liu

Xinyu Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinyu Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Bowen Tang

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China

    1 shared publication
  • Chenxiao Tu

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China

    1 shared publication
  • Dongyao Zhao

    Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University No. 1 Jianshe East, Zhengzhou, Henan, China

    1 shared publication
  • Han Yang

    Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University No. 1 Jianshe East, Zhengzhou, Henan, China

    1 shared publication
  • Hongwei Yang

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China

    1 shared publication
  • Huanan Wang

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China

    1 shared publication

Latest Publications

  • PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive angiogenesis of gastric cancer

    by Xinyu Liu, Chenxiao Tu, Hongwei Yang, Bowen Tang, Yanwei Ye, Huanan Wang


    • 1 January 2020
      • Vol. 10  (2) , 403-+

    FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway

    by Mengmeng Cheng, Yannan Jiang, Han Yang, Dongyao Zhao, Longyu Li, Xinyu Liu

    Chemoresistance is a leading cause of tumor relapse and treatment failure in colorectal cancer (CRC) patients and is correlated with epithelial-mesenchymal transition (EMT). This study was aimed to explore the mechanism of EMT in chemoresistant CRC. Bioinformatic method was used to screen differentially expressed genes between 5-FU sensitive and resistant CRC cells. Immunohistochemistry staining was utilized to analyze the expression of FLNA in CRC tissues. The roles of FLNA in chemoresistance were validated via loss-of-function and gain-of-function experiments in vitro and in an orthotopic CRC animal model. The regulation of c-Met signaling by FLNA was explored via Co-Immunoprecipitation and luciferase reporter assays. Our results suggested FLNA directly regulated the metastasis and EMT of chemoresistant CRC cells. Moreover, c-Met- AKT mediated ser2152 phosphorylation of FLNA was demonstrated to be correlated with EMT. In turn, FLNA enhanced c-Met promoter activity by its interaction with smad2. Clinically, the expression of FLNA was significantly associated with c-Met protein levels in CRC tissues. These data established that FLNA could be a novel and reliable CRC marker and a potential therapeutic target against CRC.